Wegovy When Pregnant: What the Evidence Really Shows

The misconception: 'Wegovy is so well-studied it must be safe in pregnancy'

Semaglutide has now been through some of the largest obesity trials ever run, and that track record can create a false sense of reassurance. The STEP 1 trial, published in the New England Journal of Medicine, enrolled nearly 2,000 adults and showed around 15% average weight loss — but pregnant women were excluded from that research, as they are from almost all phase-3 drug trials. The absence of a pregnancy signal in those trials is not the same as a safety signal in favour of use during pregnancy.

Animal studies with semaglutide produced structural abnormalities in developing offspring at doses relevant to human treatment. Regulatory agencies in the UK, Europe and the US all reached the same conclusion: the medicine should not be used in pregnancy, and our guidance on whether you can take semaglutide when pregnant explains that position in full, including what the animal data showed and how regulators interpreted it. That position is reflected in the medicine's SmPC (the authorised prescribing document) and in the NHS patient information for semaglutide. What we don't have is long-term human data that might eventually change that picture. Until such data exist, the guidance stands.

It is also worth separating two related but distinct questions: whether Wegovy is harmful in pregnancy, and whether obesity itself carries pregnancy risks. The answer to the second question is yes, and that context matters when thinking about weight management before conception, which is a legitimate clinical conversation to have with your GP or a specialist.

Stopping Wegovy before pregnancy: what the guidance says about timing

NHS England's advice for women taking weight-management injections is to use effective contraception throughout treatment. The MHRA advises stopping semaglutide before trying to conceive, although it does not specify a fixed washout interval in the same way it does for some other medicines. Semaglutide has a half-life of roughly one week, meaning it clears the body over several weeks rather than days. In practice, most prescribers recommend stopping well before attempting conception rather than in the same cycle, your GP or specialist can give you a personalised recommendation based on your situation.

If you are on Wegovy and your plans around pregnancy change, the right first call is to your prescriber or GP, not to stop without a conversation. Stopping abruptly can lead to weight regain, and having a plan in place makes that transition more manageable. Our team at nume can support that conversation and, where appropriate, help you think through options once treatment safely resumes. You can also review the broader Wegovy treatment overview for context on how the medicine works and what starting or stopping involves.

Women who become pregnant unexpectedly while taking Wegovy should stop the medicine immediately, and our dedicated page on Wegovy and pregnancy covers what to do in that situation, including how to inform your midwife and what monitoring may follow. Most inadvertent early-pregnancy exposures in clinical practice do not appear to have led to fetal harm, but the database remains too small to draw firm conclusions. Report any suspected effects via the MHRA Yellow Card scheme, that's how post-approval safety data accumulates.

Breastfeeding and the period after birth

Wegovy is also not recommended during breastfeeding. Semaglutide has been detected in the milk of lactating animals, and the risk to a breastfed infant has not been established. The SmPC advises women not to use semaglutide while breastfeeding, and that guidance is reflected across UK clinical sources. If you are considering restarting treatment after your baby is born, the safest approach is to wait until breastfeeding has ended and then have a fresh clinical assessment, your health circumstances, BMI and any comorbidities may have changed, and the prescriber will want to consider all of that.

Postnatal weight management is a recognised challenge, and GLP-1 medicines can be a legitimate tool once breastfeeding is complete and clinical assessment confirms suitability. For women who are curious about what returning to treatment might look like, our free consultation is the right starting point. A prescriber reviews every application personally (the same day, on working days) so you get a clinical answer rather than an automated one.

If cost is a factor in your thinking about private treatment after pregnancy, it is worth understanding what the range of private Wegovy prices actually reflects before making a comparison.

What this means for women planning ahead

Pregnancy planning while on Wegovy (or wanting to use it after pregnancy) is a situation our prescribers hear about regularly. The key facts are straightforward: stop before trying to conceive, do not use during pregnancy or breastfeeding, and restart only after a clinical review. What is less straightforward is what to do with weight management in the intervening period, which can stretch over a year or more when pregnancy and breastfeeding are combined.

This is a conversation best had with your GP, a specialist in weight medicine, or a team like ours that can look at your full picture. General questions about how semaglutide works and what treatment involves are covered in our weight-loss treatment overview. If you have a question that is not answered there, our FAQs page covers a range of common situations, or you can reach the team directly through our contact page. The questions around Wegovy when trying to conceive are worth reading if you are at that planning stage rather than already pregnant, and if you have arrived here wondering specifically whether you can take Wegovy when pregnant, that page sets out the clinical position clearly alongside the practical steps to take.

One practical note for anyone mid-treatment who receives unexpected news: your Wegovy pen arrives in plain, unbranded packaging via DPD. If you need to stop treatment, any unused pens should be stored safely until you can discuss disposal with a pharmacist, never just discarded.